Browsing Over 57 Sessions

Sort By

MSD - Transforming the Adjuvant Treatment Paradigm in Melanoma (ID 111)

Time
08:45 - 10:15

Gilead Sciences Europe Ltd. - Triple-Negative Breast Cancer: : See Beyond the Negatives (ID 145)

Time
18:45 - 20:15

ITM Isotopen Technologien München AG - A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy (ID 102)

Time
10:30 - 12:00

Myriad Genetics - Developments in precision medicine for breast and ovarian cancers  (ID 136)

Time
08:45 - 10:15

Novartis - Improving Survival Outcomes in HR+/HER2− Advanced Breast Cancer: A Biological Perspective  (ID 126)

Time
10:30 - 12:00

Seagen - Navigating a new era in HER2+ metastatic breast cancer: Focus on HER2CLIMB  (ID 116)

Time
10:30 - 12:00

Merck Pfizer Alliance - Patient-focused care in a changing 1L advanced bladder cancer treatment landscape (ID 151)

Time
10:30 - 11:45

Medscape - A Stepwise  Approach To Managing HR+/HER2- Early Breast Cancer: From Risk Assessment To Risk Management  (ID 107)

Time
18:45 - 20:15

Advanced Accelerator Applications, a Novartis Company - Actionable Targets in Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy (ID 141)

Time
10:30 - 12:00

Illumina - Profiling Non-Small Cell Lung Cancer using Comprehensive Genomic Profiling (ID 98)

Time
08:45 - 10:15

Astellas - The evolving landscape of advanced prostate cancer (ID 131)

Time
18:45 - 20:15

Janssen - A Decade’s Perspective on Advances in Prostate Cancer (ID 122)

Time
08:45 - 10:15